Animal Models of Diabetic Neuropathic Pain

 

 Permissions and Reprints

Abstract

Diabetic neuropathy is a common complication of diabetes. It occurs in approximately 10–20% of patients with diabetes, or roughly 40–50% patients with diabetic neuropathy. However, the pathogenesis of diabetic neuropathic pain is still largely unknown. Several animal models have been used to study the underlying mechanisms for this complication. Some commonly used animal models include streptozotocin-induced rat and mouse models, diet/nutrition-induced models, combination of chemically- and nutrition-induced model, Zucker diabetic fatty rat model, type 1 insulinopenic BB/Wor and type 2 hyperinsulinemic diabetic BBZDR/Wor rat models, and transgenic/knock-out models. Even though the manifestations of diabetic neuropathic pain vary from thermal or chemical hyperalgesia, thermal or chemical hypoalgeia, allodynia, to spontaneous pain, some pathogenesis factors are shared among these symptoms. Increased AR activity, oxidative-nitrosative stress, protein kinase C, PARP and ACE activations, C-peptide deficiency, impaired neurotrophism, and proinflammatory responses have been identified in the development of diabetic neuropathic pain. This review discusses selected animal models for diabetic neuropathic pain, as well as some commonly shared pathways in these models.

• References

• 1 Bastyr 3rd EJ, Price KL, Bril V. the MBBQ Study Group . Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 2005; 27: 1278-1294
  CrossrefPubMedGoogle Scholar
• 2 Beiswenger KK, Calcutt NA, Mizisin AP. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett 2008; 442: 267-272
  CrossrefPubMedGoogle Scholar
• 3 Bennett MI, Attal N, Backonja MM et al. Using screening tools to identify neuropathic pain. Pain 2007; 127: 199-203
  CrossrefPubMedGoogle Scholar
• 4 Benstead TJ, Sangalang VE. Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition. Can J Neurol Sci 1995; 22: 192-197
  PubMedGoogle Scholar
• 5 Bierhaus A, Nawroth PP. Critical evaluation of mouse models used to study pain and loss of pain perception in diabetic neuropathy. Exp Clin Endocrinol Diabetes 2012; 120: 188-190
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Bierhaus A, Fleming T, Stoyanov S et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18: 926-933
  CrossrefPubMedGoogle Scholar
• 7 Bonner-Weir S, Trent DF, Weir GC. Responses of neonatal rat islet to streptozotocin. Limited B cell regeneration and hyperglycemia. Diabetes 1981; 30: 64-69
  CrossrefPubMedGoogle Scholar
• 8 Boulton AJ. The diabetic foot: from art to science. The 18^th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-1353
  PubMedGoogle Scholar
• 9 Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002; 50: 205-208
  PubMedGoogle Scholar
• 10 Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004; 47: 718-724
  CrossrefPubMedGoogle Scholar
• 11 Cameron NE, Cotter MA, Basso M. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-281
  CrossrefPubMedGoogle Scholar
• 12 Cameron NE, Tuck Z, McCabe L et al. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001; 44: 1161-1169
  CrossrefPubMedGoogle Scholar
• 13 Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-135
  CrossrefPubMedGoogle Scholar
• 14 Cameron NE, Gibson TM, Nangle MR et al. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005; 1043: 784-792
  CrossrefPubMedGoogle Scholar
• 15 Chaplan SR, Bach FW, Pogrel JW et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63
  CrossrefPubMedGoogle Scholar
• 16 Chen SR, Pan HL. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats. J Neuro-physiol 2002; 87: 2726-2733
  PubMedGoogle Scholar
• 17 Chiechio S, Copani A, Gereau 4th RW et al. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 2007; 21 (Suppl 1): 31-38
  PubMedGoogle Scholar
• 18 Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-88
  CrossrefPubMedGoogle Scholar
• 19 Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase Cb inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002; 103: 311-321
  PubMedGoogle Scholar
• 20 Dobretsov M, Hastings SL, Romanovsky D et al. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003; 960: 174-183
  CrossrefPubMedGoogle Scholar
• 21 Dobretsov M, Ghaleb AH, Romanovsky D et al. Impaired insulin signaling as a potential trigger of pain in diabetes and prediabetes. Int Anesthesiol Clin 2007; 45: 95-105
  CrossrefPubMedGoogle Scholar
• 22 Devor M, Seltzer S. Pathophysiology of Damaged Nerves in Relation to Chronic Pain. London, England: Churchill Livingstone; 1999
  Google Scholar
• 23 Diabetes in America 2^nd ed. NIH Publication 95-1468. Washington, DC: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995
  Google Scholar
• 24 Drel VR, Pacher P, Vareniuk I et al. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocindiabetic mice. Eur J Pharmacol 2007; 569: 48-58
  CrossrefPubMedGoogle Scholar
• 25 Drel VR, Pacher P, Vareniuk I et al. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. Int J Mol Med 2007; 20: 783-792
  PubMedGoogle Scholar
• 26 Eaton SE, Harris ND, Ibrahim S et al. Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia 2003; 46: 934-939
  CrossrefPubMedGoogle Scholar
• 27 Ellis EA, Grant MB, Murray FT et al. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 1998; 24: 111-120
  CrossrefPubMedGoogle Scholar
• 28 Francis G, Martinez J, Liu W et al. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 2009; 58: 934-945
  CrossrefPubMedGoogle Scholar
• 29 Guberski D, Butler L, Like A. The BBZ/Wor rat: An obese animal with autoimmune diabetes. In: Shafrir E, Renold A. (eds.). Lessons from Animal Diabetes II. London: John Libbe and Company Ltd; 1988: 268-271
  Google Scholar
• 30 Hall KE, Sima AA, Wiley JW. Voltage-dependent calcium currents are enhanced in dorsal root ganglion neurones from the Bio Bred/Worchester diabetic rat. J Physiol 1995; 486 (Pt 2) 313-222
  PubMedGoogle Scholar
• 31 Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: Clinical and research application in neuropathic pain states. Pain 2007; 129: 256-259
  CrossrefPubMedGoogle Scholar
• 32 Hemmes RB, Schoch R. High dosage testosterone propionate induces copulatory behavior in the obese male Zucker rat. Physiol Behav 1988; 43: 321-324
  CrossrefPubMedGoogle Scholar
• 33 Ilnytska O, Lyzogubov VV, Stevens MJ et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006; 55: 1686-1694
  CrossrefPubMedGoogle Scholar
• 34 Islam MS, Choi h. Nongenetic model of type 2 diabetes: a comparative study. Pharmacology 2007; 79: 243-249
  CrossrefPubMedGoogle Scholar
• 35 Jafarnejad A, Bathaie SZ, Nakhjavani M et al. Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. Life Sci 2008; 82: 301-307
  CrossrefPubMedGoogle Scholar
• 36 Jolivalt CG, Vu Y, Mizisin LM et al. Impaired prosaposin secretion during nerve regeneration in diabetic rats and protection of nerve regeneration by a prosaposin-derived peptide. J Neuropathol Exp Neurol 2008; 67: 702-710
  CrossrefPubMedGoogle Scholar
• 37 Jolivalt CG, Lee CA, Ramos KM et al. Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain 2008; 140: 48-57
  CrossrefPubMedGoogle Scholar
• 38 Kage K, Niforatos W, Zhu CZ et al. Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat. Exp Brain Res 2002; 147: 511-519
  CrossrefPubMedGoogle Scholar
• 39 Kalichman MW, Dines KC, Bobik M et al. Nerve conduction velocity, laser Doppler flow, and axonal caliber in galactose and streptozotocin diabetes. Brain Res 1998; 810: 130-137
  CrossrefPubMedGoogle Scholar
• 40 Lenzen S. The mechanisms of allxan- and strptozotcin-induced diabetes. Diabetologia 2008; 51: 216-226
  CrossrefPubMedGoogle Scholar
• 41 Li F, Drel VR, Szabó C et al. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 2005; 54: 1514-1522
  CrossrefPubMedGoogle Scholar
• 42 Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant. Treatment in experimental diabetic neuropathy. Diabetes 1997; 46 (Suppl. 01) S38-S42
  CrossrefPubMedGoogle Scholar
• 43 Luo J, Quan J, Tsai J et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998; 47: 663-668
  CrossrefPubMedGoogle Scholar
• 44 Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998; 76: 151-157
  CrossrefPubMedGoogle Scholar
• 45 Meller ST, Pechman PS, Gebhart GF et al. Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience 1992; 50: 7-10
  CrossrefPubMedGoogle Scholar
• 46 Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2^nd ed. Seattle, Wa: IASP Press; 1994
  Google Scholar
• 47 Mondelli M, Aretini A, Baldasseroni A. Distal symmetric polyneuropathy in diabetes. Differences between patients with and without neuropathic pain. Exp Clin Endocrinol Diabetes 2012; 120: 45-50
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Mordes JP, Bortell R, Blankenhorn EP et al. Rat models of type 1 diabetes: Genetics, environment, and autoimmunity. ILAR J 2004; 45: 277-290
  PubMedGoogle Scholar
• 49 Morrow TJ. Animal models of painful diabetic neuropathy: the STZ rat model. Curr Protoc Neurosci 2004; Chapter 9 Unit 9.18
  PubMedGoogle Scholar
• 50 Mousa SA, Shaqura M, Khalefa BI et al. Rab7 silencing prevents μ-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy. Diabetes 2013; 62: 1308-1319
  CrossrefPubMedGoogle Scholar
• 51 Nakamura J, Kato K, Hamada Y et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-2095
  CrossrefPubMedGoogle Scholar
• 52 Natarajan R, Nadlerm JL. Lipoxygenases and lipid signaling in vascular cells in diabetes. Frontiers in Bioscience 2003; 8 (Suppl. 01) s783-s795
  CrossrefPubMedGoogle Scholar
• 53 Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2004; 24: 1542-1548
  CrossrefPubMedGoogle Scholar
• 54 Obrosova IG, Drel VR, Oltman CL et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007; 293: E1645-E1655
  CrossrefPubMedGoogle Scholar
• 55 Obrosova IG, Van Huysen C, Fathallah L et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. The FASEB Journal 2002; 16: 123-125
  PubMedGoogle Scholar
• 56 Obrosova IG, Xu W, Lyzogubov VV et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008; 44: 972-981
  CrossrefPubMedGoogle Scholar
• 57 Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 2009; 6: 638-647
  CrossrefPubMedGoogle Scholar
• 58 Oltman CL, Davidson EP, Coppey LJ et al. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 2008; 16: 82-89
  CrossrefPubMedGoogle Scholar
• 59 Oltman CL, Davidson EP, Coppey LJ et al. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab 2009; 11: 223-233
  CrossrefPubMedGoogle Scholar
• 60 Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early?. Nat Rev Endocrinol 2011; 7: 682-690
  CrossrefPubMedGoogle Scholar
• 61 Pittenger GL, Ray M, Burcus NI et al. Intraepidermal nerve fibers are indicators of small fiber neuropathy in both diabetic and non-diabetic patients. Diabetes Care 2004; 27: 1974-1979 69
  CrossrefPubMedGoogle Scholar
• 62 Pittenger GL, Mehrabyan A, Simmons K et al. Small fiber neuropathy is associated with the metabolic syndrome. Metabolic Syndrome and Related Disorders 2005; 3: 113-121
  CrossrefPubMedGoogle Scholar
• 63 Portha B, Giroix MH, Serradas P et al. Cellular basis for glucose refractoriness of pancreatic B-cells in non insulin dependent diabetes. In Flatt PR, Lenzen S. (eds.). Insulin secretion and pancreatic B cell research. UK: Smith-Gordon; 1994: 461-472
  Google Scholar
• 64 Qiang X, Satoh J, Sagara M et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced dia: betic rats. Diabetologia 1998; 41: 1321-1326
  CrossrefPubMedGoogle Scholar
• 65 Quattrini C, Harris ND, Malik RA et al. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care 2007; 30: 655-659
  CrossrefPubMedGoogle Scholar
• 66 Ramos KM, Jiang Y, Svensson CI et al. Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007; 56: 1569-1576
  CrossrefPubMedGoogle Scholar
• 67 Reed MJ, Meszaros K, Entes LJ et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000; 49: 1390-1394
  CrossrefPubMedGoogle Scholar
• 68 Richard S, Jonathan S, Paul Z et al. IDF Diabetes Atlas. fourth edition http://www.idf.org/diabetesatlas Accessed July 28 2013
  Google Scholar
• 69 Schmidt RE, Dorsey DA, Beaudet lN et al. Analysis of the Zucker Diabetic Fatty (ZDF) Type 2 Diabetic Rat Model Suggests a Neurotrophic Role for Insulin/IGF-I in Diabetic Autonomic Neuropathy. Am J Pathol 2003; 163: 21-28
  CrossrefPubMedGoogle Scholar
• 70 Schreiber AK, Neufeld M, Jesus CH et al. Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats. Neuropharmacology 2012; 63: 1286-1297
  CrossrefPubMedGoogle Scholar
• 71 Shafrir E, Ziv E, Mosthaf L. Nutritionally induced insulin resistance and receptor defect leading to b cell failure in animal models. Ann NY Acad Sci 1999; 892: 223-246
  CrossrefPubMedGoogle Scholar
• 72 Shafrir E. Diabetes in animals: Contribution to the understanding of diabetes by study of its etiopathology in animal models. In: Porte D, Sherwin RS, Baron A. (eds.). Diabetes mellitus. NewYork. McGraw-Hill; 2003: 231-255
  Google Scholar
• 73 Shun CT, Chang YC, Wu HP et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 2004; 127: 1593-1605
  CrossrefPubMedGoogle Scholar
• 74 Sima AA, Sugimoto K. Experimental diabetic neuropathy: An update. Diabetologia 1999; 42: 773-788
  CrossrefPubMedGoogle Scholar
• 75 Sima AA, Zhang W, Xu G et al. A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia 2000; 43: 786-793
  CrossrefPubMedGoogle Scholar
• 76 Siwy J, Zoja C, Klein J et al. Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. PLoS One 2012; 7: e51334
  CrossrefPubMedGoogle Scholar
• 77 Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007; 125: 451-472
  PubMedGoogle Scholar
• 78 Sumner CJ, Sheth S, Griffin JW et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111
  CrossrefPubMedGoogle Scholar
• 79 Surwit RS, Kuhn CM, Cochrane C et al. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988; 37: 1163-1167
  CrossrefPubMedGoogle Scholar
• 80 Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physio Res 2001; 50: 536-546
  PubMedGoogle Scholar
• 81 Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Experimental biology and medicine 2012; 237: 481-490
  CrossrefPubMedGoogle Scholar
• 82 Tegeder I, Costigan M, Griffin RS et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006; 12: 1269-1277
  CrossrefPubMedGoogle Scholar
• 83 Vareniuk I, Pavlov IA, Obrosova IG. Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes. Diabetologi 2008; 51: 2126-2133
  PubMedGoogle Scholar
• 84 Velasquez MT, Kimmel PL, Michaelis IV OE. Animal models of spontaneous diabetic kidney disease. FASEB J 1990; 4: 2850-2859
  PubMedGoogle Scholar
• 85 Vera G, López-Miranda V, Herradón E et al. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. Pharmacol Biochem Behav 2012; 102: 335-343
  CrossrefPubMedGoogle Scholar
• 86 Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9: 660-674
  CrossrefPubMedGoogle Scholar
• 87 Vinik AI, Suwanwalaikorn S, Stansberry KB et al. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995; 18: 574-584
  CrossrefPubMedGoogle Scholar
• 88 Vogel HG, Vogel WH.. Drug discovery and evaluation; Pharmacological assays. Heidelberg, Berlin: Springer-Verlag; 1997
  CrossrefGoogle Scholar
• 89 Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53 (Suppl. 03) S215-S219
  CrossrefPubMedGoogle Scholar
• 90 WHO Country and regional data on diabetes http://www.who.int/diabetes/facts/world_figures/en/ Accessed November 19, 2013
  PubMed
• 91 Xu X, Liu Z, Liu H et al. The effects of galanin on neuropathic pain in streptozotocin-induced diabetic rats. Eur J Pharmacol 2012; 680: 28-33
  CrossrefPubMedGoogle Scholar
• 92 Yagihashi S, Yamagishi SI, Wada RI et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001; 124: 2448-2458
  CrossrefPubMedGoogle Scholar
• 93 Yan JE, Yuan W, Lou X et al. Streptozotocin-induced diabetic hyperalgesia in rats is associated with upregulation of Toll-like receptor 4 expression. Neurosci Lett 2012; 526: 54-58
  CrossrefPubMedGoogle Scholar
• 94 Zhang F, Ye C, Li G et al. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim 2003; 52: 401-407
  CrossrefPubMedGoogle Scholar
• 95 Zhang JL, Yang JP, Zhang JR et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathic rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res. 2013; Epub 2012 Nov 23
  PubMedGoogle Scholar